AM
Alvino Mark
Director
BoardM
€298,784
▼ Sales (11 ops.)
Insider track record
Board DirectorAcross 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Discover the full record of transactions filed by Alvino Mark, Director. Officer active across 1 company, notably Abeona Therapeutics INC.. Cumulatively, 20 filings have been published. Breakdown: 0 buy · 11 sells. Total volume traded: €299k. Activity tracked since 25 May 2021. The latest transaction was disclosed on 26 May 2026 (Don). Regulator: SEC (Form 4). The full history is openly available.
Declarations20 total
500 shares0Common StockSEC:0001493152-26-025258:0
6,500 shares@ US$5.45580.011% mcap5.6% of flowCommon StockSEC:0001493152-26-025085:0
37,313 shares0Common StockSEC:0001493152-26-003804:0
2,000 shares@ US$6.382.1% of flowCommon StockSEC:0001641172-25-012556:0
8,000 shares@ US$5.687.4% of flowCommon StockSEC:0001641172-25-011289:0
36,101 shares0Common StockSEC:0001493152-25-004749:0
4,000 shares@ US$5.383.8% of flowCommon StockSEC:0001493152-25-004437:0
4,000 shares@ US$5.103.6% of flowCommon StockSEC:0001493152-25-003052:0
11,797 shares0Common StockSEC:0001493152-24-034050:0
23,611 shares0Common StockSEC:0001493152-24-026644:0
25,890 shares@ US$4.5119.8% of flowCommon StockSEC:0001493152-24-024528:0
7,084 shares@ US$5.116.1% of flowCommon StockSEC:0001493152-24-003193:0
6,316 shares@ US$3.91458.3% of flowCommon StockSEC:0001493152-23-034856:0
58,689 shares@ US$4.6245.6% of flowCommon StockSEC:0001493152-23-021652:0
887 shares@ US$3.250.5% of flowCommon StockSEC:0001493152-23-015587:0
13,400 shares0Common StockSEC:0001493152-22-027042:0
20,000 shares@ US$0.15490.0010% mcap36.7% of flowCommon StockSEC:0001493152-22-017168:0
35,000 shares@ US$0.15610.0018% mcap63.3% of flowCommon StockSEC:0001493152-22-016079:0
77,181 shares0Common StockSEC:0001493152-21-013118:0
77,181 shares0Common StockSEC:0001493152-21-013118
About Alvino Mark
Mark Alvino is a Board Member at Abeona Therapeutics Inc. He contributes to the governance of the company and the development of its strategy. His expertise in the biotechnology field is valuable to the board.